Abstract:Background Allogeneic stem cell transplantation can cure relapsed/refractor (R/R) AML via grafted T cells versus leukemia effect, but not a viable option to many patients. By combining azacitidine with nivolumab, we harnessed T cell activity and demonstrated 33% response rates. The tumor microenvironment (TME) factors impacting response and resistance to PD-1 blockade-based treatment in AML are unknown. Methods We performed single cell RNA sequencing (scRNAseq) on 113,394 bone marrow (BM) cells, paired with >30,000 single cell T cell receptor (scTCR) repertoires, from 8 pre- and 14 post- azacitidine/nivolumab treatment aspirates of 8 R/R AML patients (median age 73 years; 3 responders; 3 non-responders; 2 stable disease) (figure 1). Results Inferred copy number loss of chromosome 7/7q (chr7/7q) by scRNAseq was associated with resistance to azacitidine/nivolumab (figure 2A), which was validated in a larger cohort based on clinical karyotyping (figure 2B). There was significant enrichment (q<0.005) for IFNg pathway in chr7/7q. We identified marked variation in the T cell components across AML patients at pre- and post- treatment, demonstrating significant dynamic changes in CD4, CD8 and non-classical T cells populations, including MAIT (figure 3A-B). Among CD8 cells, we identified a unique GZMK-enriched population that was highest at pretreatment in responders. Pseudotemporal trajectory analysis revealed a continuum of CD8 cell states, intermediated by the less exhausted, GZMK-enriched CD8 population (figure 3C-D). GZMK also discriminated between 2 MAIT populations. GZMK-enriched cells had increased expression of the stem-like T cell transcription factor TCF7, and the T cell memory transcription factor EOMES. GZMK expression was associated with improved survival in de novo TCGA AML cohort (p=0.0017). scTCR clonotype assessment revealed shared clonotypes with the terminally effector CD8 CTL cells following PD-1 blockade. Following treatment, novel clones represented 38.7% (39/101) of total clones, followed by contracted clones (32.6%) and expanded (28.7%) clones (figure 3E-F). However, 76.9% and 72.4% of novel and expanded clones were contributed by the responders. Non-responders contributed only 5% and 3.4% of the novel and expanded clones, respectively. Conclusions Chr7/7q loss is associated with resistance to PD-1 blockade. CD8 cells exist in a continuum in BMs of patients with AML and GZMK expression identifies a stem-like, memory T cell subset. The subverted T cells can be reinvigorated via PD-1 blockade and induce responses in AML driven via novel and expanded clones demonstrating AML T cell plasticity and adaptability. Further functional characterization of GZMK expressing lymphocytes in mediating antileukemic responses is underway. Ethics Approval The study was approved by IRB at MD Anderson Cancer Center

ZEB1 shapes AML immunological niches, suppressing CD8 T cell activity while fostering Th17 cell expansion

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity

ZEB1 transcription factor promotes immune escape in melanoma

Zeb1 represses TCR signaling, promotes the proliferation of T cell progenitors and is essential for NK1.1+ T cell development

ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions

Macrophages foster adaptive anti-tumor immunity by ZEB1-dependent cytotoxic T cell chemoattraction

Zeb1 maintains long-term adult hematopoietic stem cell function and extramedullary hematopoiesis

Exploring the contribution of Zfp521/ZNF521 on primary hematopoietic stem/progenitor cells and leukemia progression

ZEB1-mediated fibroblast polarization controls inflammation and sensitivity to immunotherapy in colorectal cancer

ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape

ZBTB46 coordinates angiogenesis and immunity to control tumor outcome

744 Single Cell Profiling of Acute Myeloid Leukemia (AML) and Its Microenvironment Reveals a CD8 Continuum and Adaptable T Cell Plasticity in Response to PD-1 Blockade-Based Therapy

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma

ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells

Abstract 5628: Aberrant 3'UTR processing regulates a tumor suppressor network in AML

The cell non-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Zinc finger and BTB domain-containing protein 46 is essential for survival and proliferation of acute myeloid leukemia cell line but dispensable for normal hematopoiesis